IP Verse

Toxicity Management For Anti-Tumor Activity Of Cars - EP2872171

The patent EP2872171 was granted to The Childrens Hospital OF Philadelphia on Jan 6, 2021. The application was originally filed on Jul 12, 2013 under application number EP13817210A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2872171

THE CHILDRENS HOSPITAL OF PHILADELPHIA
Application Number
EP13817210A
Filing Date
Jul 12, 2013
Status
Granted And Under Opposition
Dec 4, 2020
Publication Date
Jan 6, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GEDEON RICHTER PHARMAOct 6, 2021MAIWALDADMISSIBLE
SECERNAOct 5, 2021SECERNAWITHDRAWN
BOULT WADE TENNANTSep 24, 2021BOULT WADE TENNANTADMISSIBLE
STRAWMANFeb 22, 2021VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2009325167
INTERNATIONAL-SEARCH-REPORTUS2010273797
INTERNATIONAL-SEARCH-REPORTWO2012079000
OPPOSITIONEP3338794
OPPOSITIONWO2011066371
OPPOSITIONWO2012079000
OPPOSITIONWO2013033626
OPPOSITIONWO2014011984

Non-Patent Literature (NPL) Citations (87) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- MORGAN ET AL., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ErbB2.", MOL THER., (20100223), vol. 18, no. 4, pages 843 - 851, XP055023624
INTERNATIONAL-SEARCH-REPORT- KALOS ET AL., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia.", SCI TRANSL MED., (20110810), vol. 3, no. 95, pages 1 - 21, XP002667262
OPPOSITION- Anonymous, "Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", NATIONAL INSTITUTE OF HEALTH, (20100600), pages 1 - 196, XP055863896
OPPOSITION- Anonymous, "European Medicines Agency Evaluation of Medicines for Human Use", EMA Assessment Report for tocilizumab, (20090200), pages 1 - 55, URL: https://www.ema.europa.eu/en/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf, XP055863823
OPPOSITION- Anonymous, "Temsiroliumus", Wikipedia, Wikipedia, (20090218), pages 1 - 2, Wikipedia, (20230309), XP093030396
OPPOSITION- "antiCD19 CAR T- cell therapy", Summary of Product Characteristics (Annex I) for Kymriah, URL: https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf
OPPOSITION- BRATTSAND et al., "Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies", Ailment Pharmacol Ther, (19960100), vol. 10, pages 81 - 90, XP009051961
OPPOSITION- Denise Grady, "In Girl's Last Hope, Altered Immune Cells Beat Leukemia", The New York Times, (20121200), pages 1 - 2, URL: https://www.nytimes.com/20 12/12/1 0/health/a-breakthrouQh- against-leukemia-using-altered-t- cells.html#:~text= The%20new%20genes%20program%20the,an d%2 0start%20destroyinq%20th e%20cancer, XP055760303
OPPOSITION- Esther C. de Jong, Pedro L. Vieira, Pawel Kalinski, and Martien L. Kapsenberg, "Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3", J Leukoc Biol, (19990800), vol. 66, pages 201 - 204, XP055863841
OPPOSITION- ISHII et al., "Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS", Blood, (20160000), vol. 128, no. 22, page 3358, XP055761120
OPPOSITION- Lee S; Ballow M, "Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases", Journal of Allergy and Clinical Immunology, (20100400), vol. 125, no. 4, pages 814 - 820, XP026988731
OPPOSITION- Martine Szyper-Kravitz, "The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm", Isr Med Assoc J, (20091000), vol. 11, no. 10, pages 633 - 634, XP055763019
OPPOSITION- NELLAN et al., "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques", Blood, (20180628), vol. 132, no. 6, pages 662 - 666, XP055761286
OPPOSITION- Sha Beverly E et al, "Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2", AIDS RESEARCH AND HUMAN RETROVIRUSES, US , (20020610), vol. 18, no. 9, ISSN 0889-2229, pages 661 - 665, XP009117547
OPPOSITION- WINKLER U; ET AL, "CYTOKINE-RELEASE SYNDROME IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGH LYMPHOCYTE COUNTS AFTER TREATMENT WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB, IDEC-C2B8)", Blood, (19991000), vol. 94, no. 7, pages 2217 - 2224, XP001022211
OPPOSITION- Grazyna Lipowska-Bhalla; David E Gilham; Robert E Hawkins; Dominic G Rothwell, "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", Cancer Immunol Immunother, (20120400), vol. 61, no. 7, pages 953 - 962, XP035074376
OPPOSITION- DAVILA et al., "Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies", Int. J Hematol., (20140000), vol. 99, no. 4, doi:10.1007/s12185-013-1479-5, pages 361 - 367, XP055533790
OPPOSITION- Andreas Reiff, "Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment", Biologics in Therapy, (20120101), vol. 2, no. 1, doi:10.1007/s13554-012-0001-6, XP055763396
OPPOSITION- William R Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; Douglas Rizzo J; Ayman Saad; Wael Saber; Parameswaran Hari, "Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease", Biol Blood Marrow Transplant, (20111200), vol. 17, no. 12, pages 1862 - 1868, XP028112518
OPPOSITION- William R. Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; J. Douglas Rizzo; Ayman Saad; Wael Saber; Parameswaran Hari;, "Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, US , (20110705), vol. 17, no. 12, doi:10.1016/j.bbmt.2011.07.001, ISSN 1083-8791, pages 1862 - 1868, XP028112518
OPPOSITION- TANAKA et al., "Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases", FEBS Letters, (20110000), vol. 585, doi:10.1016/j.febslet.2011.03.023, pages 3699 - 3709, XP028118458
OPPOSITION- ANURATHAPAN et al., "Engineered T cells for cancer treatment", Cytotherapy, vol. 16, no. 6, doi:10.1016/j.jcyt.2013.10.002, pages 713 - 733, XP055465916
OPPOSITION- Nina Pilat; Mohamed H Sayegh; Thomas Wekerle, "Costimulatory pathways in transplantation", Seminars in immunology, (20110500), vol. 23, no. 4, pages 293 - 303, XP028320580
OPPOSITION- Ferrara J L; Levine J E; Reddy P; Holler E, "Graft-versus-host disease", Lancet, (20090500), vol. 373, no. 9674, pages 1550 - 1561, XP026088702
OPPOSITION- Kaplanski G; Marin V; Montero-Julian F; Mantovani A; Farnarier C, "IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation", Trends in Immunol, (20030100), vol. 24, no. 1, pages 25 - 29, XP004398541
OPPOSITION- RAVELLI et al., "Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment", Genes and Immunity, (20120300), vol. 13, doi:10.1038/gene.2012.3, pages 289 - 298, XP055760284
OPPOSITION- MORGAN et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, (20100000), vol. 18, no. 4, doi:10.1038/mt.2010.24, pages 843 - 851, XP055023624
OPPOSITION- MORGAN et al., "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", Mol Ther., (20100223), vol. 18, no. 4, doi:10.1038/mt.2010.24, pages 843 - 51, XP055023624
OPPOSITION- Richard A Morgan et al, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, US , (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624
OPPOSITION- Richard A Morgan; ET AL, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Mol Ther, (20100200), vol. 18, pages 843 - 851, XP055023624
OPPOSITION- Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain, "Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial", Molecular Therapy, (20100400), vol. 18, no. 4, pages 666 - 668, XP055143817
OPPOSITION- John E Sims; Dirk E Smith, "The IL-1 family: regulators of immunity", Nat Rev Immunol, (20100100), vol. 10, pages 89 - 102, XP055122601
OPPOSITION- WEI et al., "The model of cytokine release syndrome in CAR T- cell treatment for B- cell non-Hodgkin lymphoma", Signal Transduct Target Ther., (20200729), vol. 5, no. 1, XP055761280
OPPOSITION- SUNTHARALINGAM GANESH; ET AL, "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412", The New England journal of medicine, (20060900), vol. 355, pages 1018 - 1028, XP002559375
OPPOSITION- David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", N Engl J Med, (20110800), vol. 365, no. 8, pages 725 - 733, XP002732435
OPPOSITION- David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England journal of medicine, US , (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England Journal of Medicine, (20110000), vol. 365, doi:10.1056/NEJMoa1103849, pages 725 - 733, XP055579937
OPPOSITION- GRUPP et al., "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", N Engl J Med., (20130325), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, pages 1509 - 1518, XP055169041
OPPOSITION- GRUPP et al., "Chimeric Antigen Receptor- Modified T Cells for Acute Lymphoid Leukemia", The New England Journal of Medicine, (20130325), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, pages 1509 - 1518, XP055169041
OPPOSITION- Stephan A. Grupp et al, "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", The New England journal of medicine, US , (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1509 - 1518, XP055169041
OPPOSITION- Alexander Krüttgen; Stefan Rose-John, "Interleukin-6 in Sepsis and Capillary Leakage Syndrome", J Interferon & Cytokine Res, (20111200), vol. 32, no. 2, pages 60 - 65, XP055763364
OPPOSITION- Lucrecia Yanez, Miriam Sanchez-Escamilla, Miguel-Angel Perales, "CAR T Cell Toxicity: Current Management and Future Directions", HemaSphere, (20190401), vol. 3, no. 2, doi:10.1097/HS9.0000000000000186, page e186, XP055763414
OPPOSITION- Sandilands G P; Wilson M; Huser C; Jolly L; Sands W A; McSharry C, "Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?", Clin Exp Immunol, (20101000), vol. 162, no. 3, pages 516 - 527, XP071080621
OPPOSITION- KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20110000), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, pages 1 - 11, XP002667262
OPPOSITION- KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci Transl Med., (20110810), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, XP002667262
OPPOSITION- KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci Transl Med, (20110810), vol. 3, no. 95, XP002667262
OPPOSITION- KALOS MICHAEL; ET AL, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci Tansl Med, (20110800), vol. 3, no. 95, pages 95ra73.1 - 95ra73.11, XP002667262
OPPOSITION- SULLIVAN et al., "Measurement of Cytokine Secretion, Intracellular Protein Expression, and mRNA in Resting and Stimulated Peripheral Blood Mononuclear Cells", Clin Diagn Lab Immunol., (20000000), doi:10.1128/CDLI.7.6.920-924.2000, pages 920 - 924, XP055313154
OPPOSITION- Tisoncik J R; Korth M J; Simmons C P; Farrar J; Martin T R; Katze M G, "Into the Eye of the Cytokine Storm", Microbiol Mol Biol Rev, (20120300), vol. 76, no. 1, pages 16 - 32, XP055183762
OPPOSITION- Atsushi Ogata, Toshio Tanaka, "Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions", International Journal of Rheumatology, (20120101), vol. 2012, doi:10.1155/2012/946048, ISSN 1687-9260, pages 1 - 14, XP055763394
OPPOSITION- Isao Tawara; Motoko Koyama; Chen Liu; Tomomi Toubai; Dafydd Thomas; Rebecca Evers; Peter Chockley; Evelyn Nieves; Yaping Sun; Kathleen P Lowler; Chelsea Malter; Norihiro Nishimoto; Geoffrey R Hill; Pavan Reddy, "Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation", Clin Cancer Res, (20101100), vol. 17, no. 1, pages 77 - 88, XP055763021
OPPOSITION- Isao Tawara, Motoko Koyama, Chen Liu, Tomomi Toubai, Dafydd Thomas, Rebecca Evers, Peter Chockley, Evelyn Nieves, Yaping Sun, Kathleen P. Lowler, Chelsea Malter, Norihiro Nishimoto, Geoffrey R. Hill, Pavan Reddy, "Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation", Clinical Cancer Research, (20110101), vol. 17, no. 1, doi:10.1158/1078-0432.CCR-10-1198, ISSN 1078-0432, pages 77 - 88, XP055763021
OPPOSITION- TEACHEY et al., "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T- cell Therapy for Acute Lymphoblastic Leukemia", Cancer Discov., vol. 6, no. 6, doi:10.1158/2159-8290.CD-16-0040, (20160413), pages 664 - 79, XP055314474
OPPOSITION- GUST et al., "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD 19 CAR-T Cells", Cancer Discov., vol. 7, no. 12, doi:10.1158/2159-8290.CD-17-0698, (20171012), pages 1404 - 1419, XP055590591
OPPOSITION- Simon A Jones; Jürgen Scheller; Stefan Rose-John, "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling", J Clin Invest, (20110900), vol. 121, no. 9, pages 3375 - 3383, XP055265579
OPPOSITION- Yanik G A; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; And Kenneth R Cooke, "The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell", Blood, (20080700), vol. 112, pages 3073 - 3081, XP055236431
OPPOSITION- J. N. Kochenderfer et al, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, US , (20120322), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503
OPPOSITION- KOCHENDERFER et al., "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, (20111200), vol. 119, pages 2709 - 2720, XP055145503
OPPOSITION- KOCHENDERFER ET AL., "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen- receptor-transduced T cells", Blood, vol. 119, doi: 10.1182/blood-2011-10-384388, pages 2709 - 2720, XP055145503
OPPOSITION- CORDEIRO et al., "Late Effects of CD 19-Targeted CAR-T Cell Therapy", Blood, (20180000), vol. 132, no. Supplement 1, doi:10.1182/blood-2018-99-112023, page 223, XP086592889
OPPOSITION- Molostova Olga et al, "Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities", Blood, US , (20191113), vol. 134, doi:10.1182/blood-2019-130370, ISSN 0006-4971, page 2625, XP086674619
OPPOSITION- Vadhan-Raj Saroj;et al, "Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.", Blood, US , (20091120), vol. 114, no. 22, doi:10.1182/blood.V114.22.105.105, ISSN 0006-4971, page 105, XP086688969
OPPOSITION- GRUPP et al., "CD 19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL -6 Antagonist Tocilizumab (toc).", Blood, (20120000), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, page 2604, XP086659979
OPPOSITION- GRUPP ET AL., "CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage", Blood, (20121100), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, page 2604, XP009521968
OPPOSITION- Grupp SA Porter DL Teachey DT; Barrett DM; Chew A Suppa E Levine BL Kalos M; June CH, "CD19-Redirected Chimeric Antigen Receptor T(CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab", Blood, (20121100), vol. 120, no. 21, page 2604, XP009521968
OPPOSITION- Grupp Stephan A.; Porter David L; Teachey David T; Barrett David M.; Chew Anne; Suppa Erica; Levine Bruce L.; Kalos Michael; June Carl H., "CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).", Blood, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP086659979
OPPOSITION- Porter David L; Grupp Stephan A.; Kalos Michael; Loren Alison W.; Lledo Lester; Gilmore Joan; Milone Michael C; Chew Anne; Levine Bruce L.; June Carl H., "Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.717.717, ISSN 0006-4971, page 717, XP086659443
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor T Cells Directed Against CD 19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20120000), vol. 120, no. 21, page 717, XP009511066
OPPOSITION- PORTER et al., "Chimeric Antigen Receptor T Cells Directed Against CD 19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, (20121100), vol. 120, no. 21, page 717, XP009511066
OPPOSITION- KALOS et al., "Sustained Functional T Cell Persistence and B Cell Aplasia Following CD 19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD 19+ Malignanc y", Blood, (20121100), vol. 120, no. 21, doi:10.1182/blood.V120.21.756.756, page 756, XP086661848
OPPOSITION- Breslin S, "Cytokine-release syndrome: overview and nursing implications", Clin J Oncol Nurse, (20070200), vol. 11, no. 1, pages 37 - 4 2, XP055440000
OPPOSITION- DU BOIS et al., "Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma", J Clin Oncol., (19970300), vol. 15, no. 3, doi:10.1200/JCO.1997.15.3.1052, pages 1052 - 62, XP055761070
OPPOSITION- KOCHENDERFER et al., "Chemotherapy-refractory diffuse large B- cell lymphoma and indolent B- cell malignancies can be effectively treated with autologous T cells expressing an anti- CD 19 chimeric antigen receptor", J Clin Oncol., (20150000), vol. 33, no. 6, doi:10.1200/JCO.2014.56.2025, pages 540 - 549, XP055552252
OPPOSITION- SHEN et al., "Etanercept Restores the Antinociceptive Effect of Morphine and Suppresses spinal neuroinflammation in morphine-tolerant rats", Anesthesia and analgesia, (20110000), vol. 112, no. 2, doi:10.1213/ANE.0b013e3182025b15, pages 454 - 459, XP055510432
OPPOSITION- Hao Hong Yiu; Andrea L Graham; Robert F Stengel, "Dynamics of cytokine storm", PLOS One, (20121001), vol. 7, no. 10, pages 1 - 15, XP055763358
OPPOSITION- Carlos A Ramos; Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opin Biol. Ther., (20110400), vol. 11, no. 7, pages 855 - 873, XP055122639
OPPOSITION- BRENNAN et al., "Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies", mAbs, (20100000), vol. 2, no. 3, doi:10.4161/mabs.2.3.11782, pages 233 - 255, XP055072297
OPPOSITION- David L Porter; Michael Kalos; Zhaohui Zheng; Bruce Levine; Carl June, "Chimeric antigen receptor therapy for B-cell malignancies", J Cancer, (20110600), vol. 2, pages 331 - 332, XP055247868
OTHER- KALOS MICHAEL; ET AL, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Leukemia, (20110810), vol. 3, no. 95, pages 95ra73.1 - 95ra73.11, XP002667262
OTHER- Kochenderfer J N; et al.,, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, (20111208), vol. 119, no. 12, pages 2709 - 2720, XP055145503
SEARCH- KEVIN J. CURRAN ET AL, "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions", THE JOURNAL OF GENE MEDICINE, (20120627), vol. 14, no. 6, doi:10.1002/jgm.2604, ISSN 1099-498X, pages 405 - 415, XP055081970 [A] 1-13
SEARCH- GRAZYNA LIPOWSKA-BHALLA ET AL, "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20120422), vol. 61, no. 7, doi:10.1007/S00262-012-1254-0, ISSN 1432-0851, pages 953 - 962, XP035074376 [X] 1,8-10 * the whole document *
SEARCH- RENIER BRENTJENS ET AL, "Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial", MOLECULAR THERAPY, (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.31, ISSN 1525-0016, pages 666 - 668, XP055143817 [Y] 1-13 * the whole document *
SEARCH- DAVID L. PORTER ET AL, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", NEW ENGLAND JOURNAL OF MEDICINE, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055052475 [A] 1-13
SEARCH- G. A. Yanik ET AL, "The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell", Blood, (20081015), pages 3073 - 3081, URL: http://www.bloodjournal.org/content/bloodjournal/112/8/3073.full.pdf, (20151215), XP055236431 [Y] 1-13 * the whole document *
SEARCH- J. N. KOCHENDERFER ET AL, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", BLOOD, (20111208), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 [X] 1,8-10 * the whole document *
SEARCH- CARLOS A RAMOS ET AL, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 1471-2598, pages 855 - 873, XP055122639 [A] 1-13

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents